# Valvular Assessment of New Generation Aortic Replacement Devices

Study · id `cardio:ct-nct06688448` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06688448](<https://clinicaltrials.gov/study/NCT06688448>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06688448

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06688448. Randomized; no masking; primary purpose treatment. Start 2024-12-01 (actual); primary completion 2026-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06688448, source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)
- Started: 2024-12-01 (actual) (ClinicalTrials.gov record NCT06688448, source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT06688448, source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)
- Completion: 2036-12-01 (anticipated) (ClinicalTrials.gov record NCT06688448, source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT06688448, source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06688448-2025-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Valvular Assessment of New Generation Aortic Replacement Devices
- Acronym: VANGUARD
- Condition: Aortic Regurgitation Disease
- Condition: Aortic Valve Calcification
- Condition: Bicuspid Aortic Valve Disease
- Intervention (Device): Dafodil prosthesis
- Intervention (Device): Aortic Valve Replacement - Inspires Resilia prosthesis
- Lead sponsor: Instituto Dante Pazzanese de Cardiologia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bicuspid aortic valve (`cardio:bicuspid-aortic-valve`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Instituto Dante Pazzanese de Cardiologia (`cardio:org-instituto-dante-pazzanese-de-cardiologia`)

## Provenance

Content hash: 339cfa8fae439f94ae3091a84bf037dfdcc5328c9023a4e7df3a40f4c55ca0a0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
